Supply of Menveo Meningococcal by Novartis Vaccines

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, aims to regulate the quality, safety, and efficacy of therapeutic goods in Australia. This Act was introduced to address the need for stringent control over the manufacture, supply, and advertising of therapeutic goods, ensuring that they meet the necessary standards to protect public health. One notable aspect of the Act is its provision for specific exemptions and consents to be granted under certain conditions, allowing for flexibility in the regulation of therapeutic goods while maintaining the overarching goal of safeguarding public health. The 2013 notice under sections 14 and 14A of the Act, issued by the delegate of the Secretary of the Department of Health, demonstrates this flexibility by permitting the supply of a specific batch of meningococcal vaccine under particular conditions, including non-compliance with certain labelling requirements, thereby addressing the need for timely availability of essential vaccines while ensuring safety and information transparency.

Scope and Application

The Therapeutic Goods Act 1989, as amended by the consent given on 15 October 2013, pertains specifically to the supply of MENVEO meningococcal (Groups A, C, W-135 and Y) oligosaccharide CRM197 conjugate vaccine Aust R 192696 by Novartis Vaccines & Diagnostic Pty Ltd, a company located in North Ryde, NSW. This legislation authorises an exemption for Batch No. M12045 of the vaccine, which originated in Austria and features vial labels in the German language. The exemption allows these vial labels to deviate from the requirements of Therapeutic Goods Order No 69, which stipulates the general requirements for labels for medicines. However, the exemption is conditional and applies only to this specific batch, necessitating that each vial be repacked into Australian approved outer packaging with the requisite Australian product information and the accompanying "Dear Doctor" letter. Furthermore, the repackaged batch must adhere to normal Therapeutic Goods Administration Lot Release processes. The exemption granted under this Act is narrowly tailored, affecting only the specified vaccine batch and its labelling. It does not extend to any other entities, products, or batches. The geographic scope of the Act's application is inherently tied to the Australian regulatory framework, ensuring that the therapeutic goods supplied within Australia meet the necessary standards for safety and efficacy. The consent provided by the delegate of the Secretary is subject to stringent conditions, reflecting the importance of maintaining regulatory oversight while accommodating specific circumstances.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides a framework for regulating therapeutic goods in Australia, ensuring their quality, safety, and efficacy. Sections 14 and 14A of the Act allow for certain exemptions from specific requirements, such as label conformity, under certain conditions. In this instance, the delegate of the Secretary of the Department of Health has granted an exemption for the supply of MENVEO meningococcal vaccine by Novartis Vaccines & Diagnostic Pty Ltd (section 14(a)). Additionally, the exemption allows for the vial labels of the vaccine not to conform with the requirements of Therapeutic Goods Order No 69 (section 14(a)(b)). These exemptions are subject to specific conditions, including that the exemption applies only to a particular batch (Batch No. M12045) of the vaccine from Austria, which has Austrian vial labels in German (section 15(1)(a)). Under the Act, the manufacturer or supplier of therapeutic goods, in this case, Novartis Vaccines & Diagnostic Pty Ltd, must comply with the conditions set out in the exemption. The vaccine must be repacked into Australian approved outer packaging (carton) with Australian product information (PI) and must be accompanied by the “Dear Doctor” letter submitted to the Therapeutic Goods Administration (TGA) on 11 October 2013 (section 15(1)(b)). Furthermore, the repackaged batch must undergo normal TGA Lot Release processes to ensure compliance with the Act's standards (section 15(1)(c)). Failure to comply with the conditions outlined in the exemption, or any other provisions of the Act, may result in legal consequences. The Act provides for both civil and criminal penalties for breaches. Civil penalties may include fines, while criminal penalties may involve imprisonment, fines, or both, depending on the severity of the breach. The maximum penalties for offences under the Act are specified in section 33DA and can include fines of up to $22,200 for individuals and $111,000 for bodies corporate, as well as imprisonment for up to two years for individuals and five years for bodies corporate. These penalties underscore the importance of compliance with the Act and its regulations to ensure the safety and efficacy of therapeutic goods supplied in Australia.